Table 1.

Biomarkers as predictors for therapy response to specific cytostatic drugs.

Drug	Biomarker	Source	Prognosis	Evidence	Ref.
Gemcitabine	hENT1-high	Tumor	↑	IB	[84]
	Exosomal miRNA-106b	Blood	↓	Preclinical	[110]
	Deoxycytidine kinase	Tumor	↓	Preclinical	[89]
	SPARC	Tumor	↓	Preclinical	[96]
Nab-Paclitaxel	CA19-9	Blood	↓	IB	[77]
5-FU	Multidrug resistance associated protein 5	Tumor	↓	Preclinical	[98]
	Dihydropyrimidine dehydrogenase	Tumor	↓	IB	[100]
Irinotecan	Carboxylesterase 2	Tumor	↑	III	[104]
Nal-Irinotecan	IL8	Blood	↓	Preclinical	[105]
Oxaliplatin	ERCC1	Tumor	↓	III	[107]
	BRCA1/2, PALB2	Serum	↑	III	[111]